Myeloma Paper of the Day, July 12th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Study of single-point and kinetics of residual disease measured by mass spec suggests it may better predict outcome in high risk smoldering myeloma vs. classical International Myeloma Working Group (IMWG) response criteria based on cohort from GEM-CESAR trial.”
Source: Robert Orlowski/X
Authors: Noemí Puig, Cristina Agulló, Teresa Contreras, José-Juan Pérez, Irene Aires, María-José Calasanz, Ramón García-Sanz, Sergio Castro, Joaquín Martínez-López, Paula Rodríguez-Otero, Verónica González-Calle, Marta S González, Albert Oriol, Norma C Gutiérrez, Rafael Ríos-Tamayo, Laura Rosiñol, Miguel-Ángel Álvarez, Joan Bargay, Ana-Pilar González-Rodríguez, Adrián Alegre, Fernando Escalante, María-Belén Iñigo, Javier de la Rubia, Ana-Isabel Teruel, Felipe de Arriba, Luis Palomera, Miguel T Hernández, Javier López-Jiménez, Marta Reinoso, Aránzazu García-Mateo, Enrique M Ocio, Joan Bladé, Juan-José Lahuerta, María-Teresa Cedena, Bruno Paiva, Jesús F San Miguel and María-Victoria Mateos.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023